Sera Prognostics Inc’s Q4 2024 Earnings Call: A Peek into the Future of Pregnancy-Related Health
On a crisp afternoon in March 2025, the financial world tuned in for the Sera Prognostics Inc (NASDAQ: SERA) earnings conference call. With anticipation in the air, investors, analysts, and industry professionals gathered to discuss the company’s financial performance during the fourth quarter of fiscal year 2024.
Company Leadership
The call was moderated by Peter DeNardo, Senior Vice President of Investor Relations at CapComm Partners, and featured Evguenia Lindgardt, President, CEO, and Director at Sera Prognostics, and Austin Aerts, the company’s Chief Financial Officer. The trio was joined by Dan Brennan from TD Cowen and Margarate Boeye from William Blair, who participated as conference call guests.
Fourth Quarter Financial Highlights
The call began with the usual financial formalities. The team shared that Sera Prognostics had reported revenue of $12.5 million for the quarter, marking a significant 58% increase year-over-year. Net loss for the quarter was reported at $10.3 million, a decrease from $11.8 million in the same quarter the previous year. Total revenue for the fiscal year 2024 was $38.4 million, up from $25.5 million in the previous fiscal year.
Business Updates
CEO Evguenia Lindgardt discussed the company’s progress in the market, sharing that Sera Prognostics had gained FDA approval for its PreTRM test in January 2025. The test, which identifies pregnant women at high risk for preterm labor, is a game-changer in the healthcare industry. This approval marks a significant milestone for Sera Prognostics and opens the door to a larger market for the company.
Impact on Individuals
For expecting parents, this means access to earlier and more accurate preterm labor risk assessments. With the PreTRM test, healthcare providers can offer personalized care plans to high-risk patients, potentially reducing the number of premature births and improving outcomes for both mothers and babies. This could lead to a more peaceful and less stressful pregnancy experience for many.
Impact on the World
On a larger scale, the PreTRM test’s approval could bring about a seismic shift in the healthcare industry. The World Health Organization reports that approximately 15 million babies are born prematurely each year, accounting for about one in ten births worldwide. Premature birth is a leading cause of neonatal mortality and morbidity, as well as long-term health issues. By providing earlier and more accurate risk assessments, Sera Prognostics’ PreTRM test has the potential to significantly reduce the number of premature births and save countless lives.
Future Plans
In the coming months, Sera Prognostics plans to focus on expanding its reach and increasing market penetration. The company aims to collaborate with healthcare providers and insurance companies to make the PreTRM test more accessible to at-risk patients. Additionally, the team is exploring potential partnerships to expand the test’s application to other indications and markets.
Wrap Up
The Sera Prognostics Q4 2024 earnings call was a testament to the company’s dedication to improving pregnancy-related health outcomes. With the FDA approval of the PreTRM test, Sera Prognostics is poised to make a significant impact on the lives of countless expecting parents and their babies. As the company continues to grow and innovate, it will undoubtedly change the way healthcare professionals approach preterm labor risk assessments and prenatal care.
- Sera Prognostics reported $12.5 million in revenue for Q4 2024, a 58% increase year-over-year.
- The company gained FDA approval for its PreTRM test in January 2025.
- The PreTRM test identifies pregnant women at high risk for preterm labor, improving pregnancy outcomes and potentially saving lives.
- Sera Prognostics plans to expand market reach and collaborate with healthcare providers and insurance companies to increase test accessibility.
As we look to the future, it’s clear that Sera Prognostics is making strides in the world of pregnancy-related healthcare. By providing earlier and more accurate risk assessments, the company is paving the way for a healthier future for both mothers and babies.
